|
KR20160111988A
|
|
Novel CYP-Eicosanoid Derivatives
|
|
US2016008339A1
|
|
Psoralen derivatives for preventing or treating heart failure or cardiac hypertrophy
|
|
EP2692354A1
|
|
Means for treating heart disease
|
|
EP2669697A2
|
|
An array of radiative antenna elements enclosed in a flexible dielectric medium for combined MR imaging and RF hyperthermia
|
|
EP2644093A1
|
|
Method for diagnosis of acute kidney injury using magnetic resonance imaging
|
|
EP2644092A1
|
|
Method for localisation and/or quantification of 19F-containing compounds via 19F magnetic resonance (MR) analysis after topical administration
|
|
US2013300410A1
|
|
Method for fast spin-echo MRT imaging
|
|
WO2013135910A1
|
|
Method for identification of the sequence of poly(a)+rna that physically interacts with protein
|
|
GB2508414A
|
|
Tumour specific T cell receptors (TCRs)
|
|
EP2682118A1
|
|
Psoralen derivatives for the treatment of heart failure and heart hypertophy
|
|
WO2012143377A1
|
|
Niclosamide for the treatment of cancer metastasis
|
|
EP2529738A1
|
|
Substituted terpyridines
|
|
WO2012041524A1
|
|
Hydrazonopyrazolones as protein tyrosine phosphatase inhibitors
|
|
EP2508186A1
|
|
Phenoxazinones or phenothiazones as inhibitors of amyloid formation
|
|
WO2011117305A1
|
|
Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates
|
|
EP2492704A1
|
|
MRI flow measurement with additional sensor for selection of VENC
|
|
EP2491858A1
|
|
Magnetic resonance tomography (MRT) apparatus and method of operating a magnetic resonance (MR) apparatus
|
|
EP2460890A1
|
|
Gpnmb/Osteoactivin as a drug target and biomarker in cardiac diseases
|
|
EP2420245A1
|
|
Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth
|
|
EP2397559A1
|
|
Stage-specific biomarkers for the diagnosis of acute kidney injury
|
